An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new clinical guideline from the U.S. Department of Veterans Affairs (VA) and the Department of Defense (DoD) says doctors should strongly consider prescribing two drugs, semaglutide and tirzepatide, for treating obesity. That’s the headline: these two medicines are now being recommended more firmly than before in official guidance for military and veteran health systems. Semaglutide and tirzepatide are drugs that mimic hormones your gut uses to tell your brain about hunger and fullness. Semaglutide acts like a hormone called GLP-1 (glucagon-like peptide-1) which helps you feel full and slows how fast your stomach empties. Tirzepatide does something similar but hits two hormone signals at once (GLP-1 and GIP), which can affect appetite and blood sugar control. Both are given by injection and were originally developed to treat diabetes before doctors started using them for weight loss. The guideline itself is a recommendation from health authorities about how to treat obesity; it’s not a new experiment. It’s based on clinical trial evidence that showed these drugs can produce sizable weight loss for many people compared with older treatments or placebo. The guidance’s “strong” language means the committee believes the benefits outweigh harms for many patients with obesity. The snippet doesn’t give trial sizes or exact numbers, so I can’t say how much weight loss to expect or how many people were studied — but we know from other published trials that some people lose a significant percent of body weight on these medicines, while others have smaller responses. Why this matters: official guidelines influence what doctors offer and what insurers will cover. If the VA/DoD recommends these drugs strongly, veterans and active-duty personnel with obesity are more likely to be offered semaglutide or tirzepatide as a primary treatment option. More broadly, it signals growing medical acceptance of these medicines for weight management, which could affect access, insurance coverage, and how primary care clinicians discuss obesity with patients. There are important caveats. These drugs can cause side effects like nausea, diarrhea, or stomach upset, especially when treatment starts. They are injections, require ongoing use to keep benefits, and their long-term safety profile for weight loss in broad populations is still being studied. They aren’t suitable for everyone — people with certain medical histories (like some types of pancreatitis or personal/family history of thyroid cancer) may be advised against them. Also, guidelines reflect current evidence and expert judgment; they don’t change drug approval status or guarantee coverage in every case. Bottom line: The VA and DoD are now strongly recommending semaglutide and tirzepatide as treatments for obesity, which could expand access and use, but individuals should discuss risks, benefits, and alternatives with their clinician.
Source: U.S. Medicine